| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.
The Company entered into an employment agreement with Dr. Waksal for an unspecified term (the “Waksal Employment Agreement”). Under the terms of the Waksal Employment Agreement, Dr. Waksal will receive an annual base salary of $200,000. In the event the Company consummates a change in control where the “market capitalization” (as such term is defined in the Waksal Employment Agreement) of the Company equals or exceeds minimum value of $750 million, Dr. Waksal shall be entitled to a cash bonus in the amount of 1% of such market capitalization (“Waksal Transaction Bonus”).
If the Company terminates the employment of Dr. Waksal without “cause” or Dr. Waksal resigns for “good reason” (as each such terms are defined in the Waksal Employment Agreement), subject to Dr. Waksal’s timely execution of a release of claims and continued compliance with a separate restrictive covenant agreement (described below), Dr. Waksal is entitled to receive (i) base salary continuation for a period of 12 months; (ii) direct payment of or reimbursement for continued medical, dental and vision coverage pursuant to COBRA for up to 12 months, less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on Dr. Waksal’s termination date; and (iii) any options issued to Dr. Waksal under the Inducement Award Plan or other equity plans maintained by the Company may, to the extent vested and exercisable as of the date of Dr. Waksal’s termination of employment, be exercised until the earlier of twelve months from the date of termination or the expiration date set forth in the applicable option award agreement.
If the Company terminates Dr. Waksal without “cause” or Dr. Waksal resigns for “good reason,” in either case, on or within three months prior to or 12 months following a “change in control” (as defined in the Waksal Employment Agreement), then, in lieu of the severance benefits described above, subject to Dr. Waksal’s timely execution of a release of claims, Dr. Waksal is entitled to receive (i) base salary continuation for a period of 18 months; (ii) direct payment of or reimbursement for continued medical, dental and vision coverage pursuant to COBRA for up to 18 months, less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on Dr. Waksal’s termination date; (iii) accelerated vesting of all unvested equity or equity-based awards that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement; and (iv) the Waksal Transaction Bonus to the extent the conditions for issuance under the Waksal Employment Agreement are otherwise satisfied. Dr. Waksal has agreed to refrain from competing with us while employed and following his termination of employment for any reason other than by the Company without “cause” for a period of one year and to refrain from soliciting our employees or customers while employed and following his termination of employment for any reason for a period of one year.
On February 16, 2022, the Board approved the adoption of the Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Award Plan”), which was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (“Rule 5635(c)(4)”). In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee’s entering into employment with the Company or its subsidiary. An aggregate of 520,000 shares of the Company’s common stock have been reserved for issuance under the Inducement Award Plan.
In connection with his appointment as an executive officer, Dr. Waksal was granted an option to purchase 520,000 shares of the Company’s common stock under the Inducement Award Plan (the “Initial Option”). The Initial Option issued to Dr. Waksal has an exercise price per share of $4.21, which was the closing price per share of the Company’s common stock on the date of grant of the option. The Initial Option vests as to one-third of the shares underlying the option, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that, except as provided below, no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested
